Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1066959

Arterial and venous thrombosis in treated patients with myeloproliferative neoplasms


Boban, Ana; Perić Morić, Martina; Zekanović, Ivan; Horvat, Ivana; Antolić Radic, Margareta; Rončević, Pavle; Zupančić-Šalek, Silva; Serventi-Seiwerth, Ranka; Kinda Bašić, Sandra.; Vrhovac, Radovan et al.
Arterial and venous thrombosis in treated patients with myeloproliferative neoplasms // HemaSphere, 3 (2019), S1; 993-994 doi:10.1097/01.hs9.0000567344.24264.ba (međunarodna recenzija, kratko priopcenje, znanstveni)


CROSBI ID: 1066959 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Arterial and venous thrombosis in treated patients with myeloproliferative neoplasms

Autori
Boban, Ana ; Perić Morić, Martina ; Zekanović, Ivan ; Horvat, Ivana ; Antolić Radic, Margareta ; Rončević, Pavle ; Zupančić-Šalek, Silva ; Serventi-Seiwerth, Ranka ; Kinda Bašić, Sandra. ; Vrhovac, Radovan ; Duraković, Nadira ; Perić, Zinaida ; Sertić, Dubravka ; Mikulić, Mirta ; Pulanić, Dražen ; Aurer, Igor

Izvornik
HemaSphere (2572-9241) 3 (2019), S1; 993-994

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kratko priopcenje, znanstveni

Ključne riječi
thrombosis ; Ph(-) MPN

Sažetak
Background: Cardiovascular and thromboembolic events are the leading causes of morbidity and mortality for patients with myeloproliferative disorders (MPN). Aims: This retrospective study aimed to evaluate the incidence and the risk factors for the arterial and venous thrombosis in treated patients with MPN. Methods: The study included 329 adult MPN patients, 184 (56%) female, treated at University Hospital Center Zagreb, Department of Internal medicine, Division of Hematology and Zadar General Hospital, Hematology Unit. Patients were aged 24-85 years (median 68), and were diagnosed as having essential thrombocythemia (ET) (n = 149, 45%), polycythaemia vera (PV)(n = 94, 29%), primary myelofibrosis (PMF)(n = 69, 21%) and unclassifiable MPN (n = 17, 5%). Diagnosis were made according to the 2008 WHO Classification. JAK-2 mutation status was either established or revised in our center, but was unknown in 55 (17%) patients. Data about treatment and cardiovascular and thromboembolic incidents was retrieved from medical records. Results: Forty patients (12%) developed thrombosis after median of 36 (range 1-240) months from the time of diagnosis. Fifteen (5%) patients developed venous thrombosis, twenty-four (7%) arterial, while one (0, 3%) patient both type of thrombosis. Regarding the disease type, thrombosis was described in 16 patients with ET (11%), 18 with PV (19%) and 6 with PMF (8%). The risk of thrombosis was the highest in patients with previous thrombotic events, but did not correlate with the type of therapy (cytoreductive and/or antiagreggation) nor the JAK-2 status. Summary/Conclusion: The risk of both arterial and venous thrombosis was found to be increased in patients with MPN even after introducing appropriate treatment. The highest risk of post treatment thrombosis was found in patients with previously diagnosed thrombotic events.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Poveznice na cjeloviti tekst rada:

doi journals.lww.com

Citiraj ovu publikaciju:

Boban, Ana; Perić Morić, Martina; Zekanović, Ivan; Horvat, Ivana; Antolić Radic, Margareta; Rončević, Pavle; Zupančić-Šalek, Silva; Serventi-Seiwerth, Ranka; Kinda Bašić, Sandra.; Vrhovac, Radovan et al.
Arterial and venous thrombosis in treated patients with myeloproliferative neoplasms // HemaSphere, 3 (2019), S1; 993-994 doi:10.1097/01.hs9.0000567344.24264.ba (međunarodna recenzija, kratko priopcenje, znanstveni)
Boban, A., Perić Morić, M., Zekanović, I., Horvat, I., Antolić Radic, M., Rončević, P., Zupančić-Šalek, S., Serventi-Seiwerth, R., Kinda Bašić, S. & Vrhovac, R. (2019) Arterial and venous thrombosis in treated patients with myeloproliferative neoplasms. HemaSphere, 3 (S1), 993-994 doi:10.1097/01.hs9.0000567344.24264.ba.
@article{article, author = {Boban, Ana and Peri\'{c} Mori\'{c}, Martina and Zekanovi\'{c}, Ivan and Horvat, Ivana and Antoli\'{c} Radic, Margareta and Ron\v{c}evi\'{c}, Pavle and Zupan\v{c}i\'{c}-\v{S}alek, Silva and Serventi-Seiwerth, Ranka and Kinda Ba\v{s}i\'{c}, Sandra. and Vrhovac, Radovan and Durakovi\'{c}, Nadira and Peri\'{c}, Zinaida and Serti\'{c}, Dubravka and Mikuli\'{c}, Mirta and Pulani\'{c}, Dra\v{z}en and Aurer, Igor}, year = {2019}, pages = {993-994}, DOI = {10.1097/01.hs9.0000567344.24264.ba}, keywords = {thrombosis, Ph(-) MPN}, journal = {HemaSphere}, doi = {10.1097/01.hs9.0000567344.24264.ba}, volume = {3}, number = {S1}, issn = {2572-9241}, title = {Arterial and venous thrombosis in treated patients with myeloproliferative neoplasms}, keyword = {thrombosis, Ph(-) MPN} }
@article{article, author = {Boban, Ana and Peri\'{c} Mori\'{c}, Martina and Zekanovi\'{c}, Ivan and Horvat, Ivana and Antoli\'{c} Radic, Margareta and Ron\v{c}evi\'{c}, Pavle and Zupan\v{c}i\'{c}-\v{S}alek, Silva and Serventi-Seiwerth, Ranka and Kinda Ba\v{s}i\'{c}, Sandra. and Vrhovac, Radovan and Durakovi\'{c}, Nadira and Peri\'{c}, Zinaida and Serti\'{c}, Dubravka and Mikuli\'{c}, Mirta and Pulani\'{c}, Dra\v{z}en and Aurer, Igor}, year = {2019}, pages = {993-994}, DOI = {10.1097/01.hs9.0000567344.24264.ba}, keywords = {thrombosis, Ph(-) MPN}, journal = {HemaSphere}, doi = {10.1097/01.hs9.0000567344.24264.ba}, volume = {3}, number = {S1}, issn = {2572-9241}, title = {Arterial and venous thrombosis in treated patients with myeloproliferative neoplasms}, keyword = {thrombosis, Ph(-) MPN} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Emerging Sources Citation Index (ESCI)


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font